AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05555316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with Lenvatinib
Description: Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg). Lenvatinib reduction standard: 8mg / day; 4mg / day; 4mg, the next day.
Study NCT02004327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M300mg
Description: DW1029M300mg PO Once
Study NCT02004327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M600mg
Description: DW1029M300mg 2 tablets Once
Study NCT02004327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M1200mg
Description: DW1029M300mg 4 tablets PO Once
Study NCT04140916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline catheter
Description: Peripherally inserted short intravenous catheter
Study NCT04140916 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC-line catheter
Description: Peripherally inserted long intravenous catheter
Study NCT02305446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
Study NCT02974920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban 10 mg once daily for 180 days
Study NCT02974920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 180 days
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-04764793 250/50 using inhaler A
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: PF-04764793 250/50 using inhaler A
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: PF-04764793 250/50 using inhaler A
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: PF-04764793 250/50 using inhaler A
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: PF-04764793 250/50 using inhaler B
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: PF-04764793 250/50 using inhaler B
Study NCT01272375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: PF-04764793 250/50 using inhaler B
Study NCT00851019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DDR
Description: Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period
Study NCT00851019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Ad libitum attendance to engage in treadmill exercise, for a 3-month period
Study NCT01156051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release tablets
Description: Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
Study NCT01156051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
Study NCT02262416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide
Description: normal saline
Study NCT01627782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
Study NCT01627782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
Study NCT01700322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
Study NCT01700322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
Study NCT01700322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
Study NCT01006499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline, pentaglobin
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
Study NCT01006499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline, pentaglobin
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
Study NCT02815059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
Study NCT02815059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
Study NCT02815059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
Study NCT01143545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Tumor Cell Vaccine (K562)
Description: Subcutaneous injection monthly for 6 months
Study NCT01143545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 g po bid
Study NCT01143545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg po bid
Study NCT04049370 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit.
Study NCT04339023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo
Description: in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)
Study NCT04339023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
Study NCT02273700 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
Study NCT00078949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00078949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00078949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00078949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT00078949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00768339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEG35156 antisense IV infusion
Description: AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~* Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~* Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion
Study NCT02627898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
Study NCT02627898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules, 400mg 1 time daily with the first bite of eat meal
Study NCT03984175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of Processes
Description: Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
Study NCT03895502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-month Edoxaban
Description: Prescription of Edoxaban for 12 months
Study NCT03895502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-month Edoxaban
Description: Prescription of Edoxaban for 3 months
Study NCT03247738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
Study NCT03247738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
Study NCT00129649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone reminder call
Study NCT02802150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zanthoxylum Schinifolium Seed Oil(4g/day)
Description: parallel design
Study NCT02802150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Bean Oil;placebo(4g/day)
Description: parallel design
Study NCT02906475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standardized skin care regimen
Description: Application of a standardized daily skin care regimen:~* milk lotion once daily and~* application of addendum for bathing as needed
Study NCT01582503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Subcutaneous repeating dose
Study NCT01582503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study NCT05383625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Description: intralesional 0.1 ml every two weeks
Study NCT05383625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalent Human Papilloma Virus Vaccine
Description: Intralesional 0.1 ml every two weeks
Study NCT05383625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intralesional into the largest warts every two weeks
Study NCT02767609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
Study NCT05509686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Description: A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
Study NCT05509686 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Description: The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
Study NCT03108872 — intervention group
Intervention type: DEVICE
Intervention: left atrial appendage occlusion
Description: Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
Study NCT03108872 — intervention group
Intervention type: DRUG
Intervention: New oral anticoagulants
Description: Include dabigatran, rivaroxaban, apixaban and edoxaban
Study NCT03727295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone/placebo
Description: The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
Study NCT03727295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idebenone/placebo
Description: The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
Study NCT03197740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch
Description: Treatment
Study NCT03197740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aricept Tab
Description: Comparator
Study NCT01429974 — intervention group
Intervention type: OTHER
Intervention: amniometer model po1
Description: The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform.
Study NCT03197077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles
Study NCT03197077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles
Study NCT03197077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal ultrasound scanning
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles
Study NCT03197077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound scanning
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles
Study NCT03197077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte retrieval for IVM
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles
Study NCT03197077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oocyte retrieval for IVM
Description: comparison between corifollitropin alfa and follitropin beta in IVM cycles
Study NCT03197077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: Single injection of 100 micrograms of corifollitropin alfa
Study NCT03197077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: Daily injection (three days) of follitropin beta
Study NCT03197077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral contraceptive pill pretreatment (Marvelon)
Description: Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
Study NCT03197077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive pill pretreatment (Marvelon)
Description: Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
Study NCT01658904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT01658904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02246218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAVICTI
Study NCT04068051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07
Description: AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
Study NCT02011217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye crisp bread A
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
Study NCT02011217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye crisp bread B
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
Study NCT02011217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat crisp bread C
Description: In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
Study NCT03551431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video EEG with verbal suggestion
Description: Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Morphine
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Methadone
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Oxycodone
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Hydromorphone
Study NCT01946555 — intervention group
Intervention type: DRUG
Intervention: Tapentadol
Study NCT01377168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Study NCT01377168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study NCT01217619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150mg/d continuously for 56 days
Study NCT02901236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Guarded Trabeculectomy
Description: A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
Study NCT02901236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
Study NCT02901236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
Study NCT04055415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose derived mesenchymal stem cells
Description: The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
Study NCT04055415 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional drug therapy（expectorant，bronchodilator）
Description: Conventional drug therapy（expectorant，bronchodilator）
Study NCT04055415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy（expectorant，bronchodilator）
Description: Conventional drug therapy（expectorant，bronchodilator）
Study NCT02762305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RSVP Bone Builders Group Exercise
Study NCT03359226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submandibular gland biopsy
Description: Needle biopsies of the right and left submandibular glands
Study NCT01789619 — intervention group
Intervention type: DRUG
Intervention: Extended release tacrolimus (Advagraf®)
Study NCT03231332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome Diversity detection
Description: detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics